BGM
DYN icon

Burkehill Global Management’s Dyne Therapeutics DYN Stock Holding History

Burkehill Global Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-155,000
Closed -$2.81M – 185
2026
Q1 		$2.81M Hold
155,000
– – 0.14% 109
2025
Q4 		$3.03M Buy
155,000
+35,000
+29% +$663K 0.2% 99
2025
Q3 		$1.52M Buy
+120,000
New +$1.37M 0.09% 127

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Burkehill Global Management's DYN Position: Q2 2026 in Review

Burkehill Global Management sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 155,000 shares — an estimated $2.81M sold.

Burkehill Global Management first reported a position in DYN in Q3 2025 and held it in 3 quarters. The position peaked at $3.03M in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Burkehill Global Management reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Burkehill Global Management sold 155,000 Dyne Therapeutics shares in Q2 2026, an estimated $2.81M.
  • Burkehill Global Management first reported a position in Dyne Therapeutics in Q3 2025 and held it in 3 quarters.
  • Burkehill Global Management's Dyne Therapeutics position peaked at $3.03M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.